3-溴-4-氯吡啶 | 36953-42-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴-4-氯吡啶
• 英文名称: 3-bromo-4-chloropyridine
• 英文别名: 3-Brom-4-chlor-pyridin
• CAS: 36953-42-1
• 化学式: C₅H₃BrClN
• mdl: MFCD00234008
• 分子量: 192.443
• InChiKey: QADXKWUCCGPQNR-UHFFFAOYSA-N

物化性质

• 熔点：
  17.5-18.5 °C
• 沸点：
  115 °C(Press: 20 Torr)
• 密度：
  1.19
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2933399090
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P280,P301+P310,P302+P352,P305+P351+P338
• 危险品运输编号：
  2810
• 危险性描述：
  H301,H315,H318,H335
• 储存条件：
  存放在阴凉干燥处即可。

SDS

Name:	3-Bromo-4-chloropyridine Material Safety Data Sheet
Synonym:
CAS:	36953-42-1

Section 1 - Chemical Product MSDS Name:3-Bromo-4-chloropyridine Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
36953-42-1	3-Bromo-4-chloropyridine		unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 36953-42-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H3BrClN
Molecular Weight: 192.44

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, acid anhydrides.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 36953-42-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Bromo-4-chloropyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 36953-42-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 36953-42-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 36953-42-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：淡黄色的液体

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  4-氯-3,5-二溴吡啶	3,5-dibromo-4-chloro-pyridine	13626-17-0	C5H2Br2ClN	271.339
  3-溴吡啶	3-Bromopyridine	626-55-1	C5H4BrN	157.997

反应信息

• 作为反应物：
  描述：

  3-溴-4-氯吡啶 在 potassium tert-butylate 、 一水合肼 、 三乙胺 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 17.0h， 生成 N-(7-(adamantan-1-ylmethoxy)-6-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methanesulfonamide
  参考文献：
  名称：

  构象约束的酰基磺酰胺类异构体的设计：N -（[1,2,4]三唑并[4,3 - a ]吡啶-3-基）甲烷-磺酰胺类化合物作为强效和选择性h Na V 1.7抑制剂的治疗鉴定疼痛

  摘要：

  钠通道Na V 1.7已经成为治疗疼痛的有前途的靶点，这是基于其在伤害感受中作用的强大遗传学验证。近年来，已经报道了许多芳基和酰基磺酰胺作为N​​a V 1.7的有效抑制剂，与心脏同工型Na V 1.5相比具有很高的选择性。在此，我们报道了一系列新的N -（[1,2,4]三唑并[4,3 - a ]吡啶-3-基）甲磺酰胺作为选择性Na V的发现。1.7抑制剂。从酰基磺酰胺的晶体结构开始，我们合理地认为，形成稠合杂环的环化将改善物理化学性质，特别是亲脂性。我们的设计策略集中于优化Na V 1.7的效价和人体代谢稳定性。铅化合物10，13（GNE-131），和25显示出优异的效力，良好的体外代谢稳定性，和低体内在小鼠，大鼠，和狗的间隙。化合物13在诱导性疼痛的转基因小鼠模型中也显示出优异的功效。

  DOI：

  10.1021/acs.jmedchem.7b01826
• 作为产物：
  描述：

  3-溴-4-硝基吡啶-N-氧化物 在 三氯化磷 作用下， 以 氯仿 为溶剂， 以78%的产率得到3-溴-4-氯吡啶
  参考文献：
  名称：

  Trecourt, Francois; Queguiner, Guy, Journal of Chemical Research, Miniprint, 1982, # 3, p. 912 - 942

  摘要：

  DOI：

文献信息

• 7-AZAINDOLE INHIBITORS OF CRAC
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158049A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

  公开了公式(I)的化合物： 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病，通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
• Inhibitors of CYP 17
  申请人：BOCK Mark G.

  公开号：US20100331326A1

  公开（公告）日：2010-12-30

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐， 其中R 53 ，R 54 ，p，q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。
• 羧酸化合物及其制备方法和用途
  申请人：益方生物科技（上海）有限公司

  公开号：CN105439946B

  公开（公告）日：2018-02-02

  本发明涉及医药技术领域，具体为由以下化学式I或化学式II表示的羧酸化合物及其药学上可接受的盐、前药、和溶剂化物及其制备方法，包含这些物质的药物组合物以及其用途。
• [EN] PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS À BASE DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT POUR LE TRAITEMENT DU CANCER
  申请人：CANCER REC TECH LTD

  公开号：WO2010041054A1

  公开（公告）日：2010-04-15

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and / or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物，以及它们作为治疗和/或预防癌症的潜在用途。
• 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING
  申请人：Sutton C James

  公开号：US20080045528A1

  公开（公告）日：2008-02-21

  Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  苯并噁唑和苯并噻唑化合物及其立体异构体、互变异构体、溶剂合物、氧化物、酯类和前药以及其药学上可接受的盐已被披露。所述化合物的组合物，无论是单独使用还是与至少一种额外治疗剂组合，并与药学上可接受的载体一起使用的用途也已被披露。这些实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或交换反应，治疗或预防癌症，治疗或预防类风湿性关节炎等退行性骨病，以及/或抑制CSF-1R等分子。